Skip to main content

Table 5 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]

From: Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

  Mainz cohort (n=158) Rotterdam cohort (n=178) Transbig cohort (n=186) Combined cohorts (n=522)
A. Univariate analysis
ER+/HER2-
AURKA P-value 0.011 <0.001 <0.001 <0.001
HR 1.786 2.916 2.174 2.100
95%-CI 1.144-2.787 2.022-4.206 1.491-3.171 1.700-2.594
  Mainz cohort ( n = 23 ) Rotterdam cohort ( n = 58 ) Transbig cohort ( n = 59 ) Combined cohorts ( n = 140 )
ER-/HER2-
AURKA P-value 0.497 0.808 0.924 0.993
HR 1.534 1.103 0.967 1.002
95%-CI 0.446-5.282 0.498-2.443 0.483-1.934 0.637-1.577
  Mainz cohort ( n = 19 ) Rotterdam cohort (n=50=) Transbig cohort (n=35) Combined cohorts (n=104)  
HER2+
AURKA P-value 0.298 0.840 0.100 0.402
HR 2.303 1.088 0.439 0.785
95%-CI 0.478-11.091 0.481-2.461 0.165-1.171 0.446-1.382
  1. AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. A. Univarate analysis.